GNLX ▲ +0.4% - Genelux Corporation $GNLX - Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy Genelux shares rose 0.4% following the company's announcement of a published deep and durable response in a platinum-relapsed small cell lung cancer patient treated with its Olvi-Vec-primed immunochemotherapy approach. The clinical data publication underscores progress in the company's oncolytic immunotherapy program for a difficult-to-treat indication with limited options. 09-SEP-2026 04:01 PM ET